What is the SENATOR project about?
SENATOR is an ambitious €6M project funded by the European Union under FP7 Programme under the topic “Active and Healthy Ageing”.
The SENATOR project started in 2012 and is focused on the development of a highly-powered and efficient software engine (SENATOR) capable of individually screening the clinical status and pharmacological and non- pharmacological therapy of older people with multi-morbidity in order to define optimal drug therapy, highlight ADR risk and provide advice on appropriate non-pharmacological therapy.
The first phase of SENATOR was the development of the SOFTWARE by ClanWilliam Health LTD. The functional software was tested and validated by comparison with a gold standard i.e. two experienced expert clinicians assessing the medication lists of 20 cases of older people with multiple chronic medical conditions and associated polypharmacy (multiple medications). Following the successful testing and validation of SENATOR software, the SENATOR consortium then embarked on a clinical trial to test the SENATOR software as an intervention compared with usual medication assessment. With the data from this randomised controlled multicenter clinical trial involving older people with multi-morbidity who are hospitalized with acute illnesses that are treated in hospital by specialists (other than geriatricians and clinical pharmacologists), the SENATOR consortium hopes to determine whether or not SENATOR software-assisted medication review offers a significant advantage over current routine medication review by attending clinicians and pharmacists in terms of reduced adverse drug reactions and associated healthcare costs as well as patient quality of life.
What patients are enrolled in SENATOR?
The SENATOR clinical trial is enrolling older people admitted to hospital with acute illnesses of many kinds under the care of clinicians other than specialists in Geriatric Medicine and Clinical Pharmacology (in order to avoid introducing bias into the trial).
The website is currently under new ownership, and the new company has expertise in assessing adult toys designed for both genders. Consequently, the website now contains the following material: